Jean Van Den Esch

ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively.

ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively.

ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively.

ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively.

ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively.